Statins and breast cancer: a smoking gun or guilt by association?

被引:6
作者
Ahmed, Mohamed H. [1 ]
Osman, Meissa M. [1 ]
Alokail, Majed S. [1 ]
机构
[1] Southampton Gen Hosp, Dept Chem Pathol, Southampton SO16 6YD, Hants, England
关键词
breast cancer; statin;
D O I
10.1517/14740338.5.5.599
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Statins are widely prescribed, effective cholesterol-lowering drugs. indeed, atorvastatin and simvastatin were the most commonly prescribed drugs in the US in 2004, with > 70 million prescriptions written for atorvastatin alone. Statins are pleiotropic agents and, after an early study of patients with coronary heart disease showed a lower than expected incidence of cancers, preclinical studies were carried out that have supported the potential anticancer activity of these compounds. However, clinical reports on the relationship between statin use and breast cancer risk have yielded mixed results, with no association and both positive and negative associations being observed. Because breast cancer is the most frequent cancer in women, any link between statin use and breast cancer risk would have major public health implications. The current evidence suggests that statins are safe and effective agents in treating hyperlipidaemia and no evidence of increase or decrease risk of breast cancer. Indeed, more research is needed to define whether long-term statin therapy may decrease or increase the risk of breast cancer.
引用
收藏
页码:599 / 601
页数:3
相关论文
共 11 条
[1]   Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors [J].
Addeo, R ;
Altucci, L ;
Battista, T ;
Bonapace, IM ;
Cancemi, M ;
Cicatiello, L ;
Germano, D ;
Pacilio, C ;
Salzano, S ;
Bresciani, F ;
Weisz, A .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 220 (03) :864-870
[2]   Tamoxifen induced-non-alcoholic steatohepatitis (NASH): Has the time come for the oncologist to be diabetologist [J].
Ahmed, M. H. ;
Osman, K. A. .
BREAST CANCER RESEARCH AND TREATMENT, 2006, 97 (02) :223-224
[3]   Rosuvastatin: A safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH) [J].
Ahmed, MH .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2006, 41 (05) :631-631
[4]   3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer -: A nested case-control study [J].
Blais, L ;
Desgagné, A ;
LeLorier, J .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (15) :2363-2368
[5]   Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies [J].
Bonovas, S ;
Filioussi, K ;
Tsavaris, N ;
Sitaras, NM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8606-8612
[6]   Statin use and breast cancer: Prospective results from the Women's Health Initiative [J].
Cauley, JA ;
McTiernan, A ;
Rodabough, RJ ;
LaCroix, A ;
Bauer, DC ;
Margolis, KL ;
Paskett, ED ;
Vitolins, MZ ;
Furberg, CD ;
Chlebowski, RT .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (10) :700-707
[7]   Statin use and the risk of breast and prostate cancer [J].
Coogan, PF ;
Rosenberg, L ;
Palmer, JR ;
Strom, BL ;
Zauber, AG ;
Shapiro, S .
EPIDEMIOLOGY, 2002, 13 (03) :262-267
[8]   Statins and cancer prevention [J].
Demierre, MF ;
Higgins, PDR ;
Gruber, SB ;
Hawk, E ;
Lippman, SM .
NATURE REVIEWS CANCER, 2005, 5 (12) :930-942
[9]   REPORT OF THE CONFERENCE ON LOW BLOOD CHOLESTEROL - MORTALITY ASSOCIATIONS [J].
JACOBS, D ;
BLACKBURN, H ;
HIGGINS, M ;
REED, D ;
ISO, H ;
MCMILLAN, G ;
NEATON, J ;
NELSON, J ;
POTTER, J ;
RIFKIND, B ;
ROSSOUW, J ;
SHEKELLE, R ;
YUSUF, S .
CIRCULATION, 1992, 86 (03) :1046-1060
[10]  
Mück AO, 2004, INT J CLIN PHARM TH, V42, P695